Filtered By:
Drug: Methotrexate
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 117 results found since Jan 2013.
Diagnostics and treatment of giant cell arteritis
Nervenarzt. 2021 Nov 3. doi: 10.1007/s00115-021-01216-8. Online ahead of print.ABSTRACTGiant cell arteritis (GCA) is the most common idiopathic systemic vasculitis in the age group over 50 years. It requires prompt diagnostics and treatment to avoid severe complications, such as visual loss or stroke. The tendency to relapse makes a glucocorticoid (GC) treatment necessary for several years and sometimes lifelong, which increases the risk of GC-induced long-term side effects. Therefore, additive GC-sparing treatment is recommended in the majority of patients. For this purpose, the anti-IL‑6 receptor antibody tocilizumab i...
Source: Der Nervenarzt - November 4, 2021 Category: Neurology Authors: Markus Kraemer Jana Becker Thorsten Alexander Bley Andreas Steinbrecher Jens Minnerup Bernhard Hellmich Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
P211 Aortitis: clinical experience within a tertiary centre
Conclusion Systemic inflammatory response syndrome was the commonest presenting feature. Those without GCA-like symptoms received a delayed diagnosis, which increases the risk of preventable vascular events. CT-PET remained the main diagnostic tool. Prednisolone treatment was prolonged with burdensome side- effects. Methotrexate remained the DMARD of choice, but leflunomide also showed good results. Vascular complications are common and need attention.Disclosure R.S. Andev: None.N. Ahmad: None.R. Luqmani: None.S. Dubey: None.
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
ConclusionRA is independently associated with poorer prognosis after MI. RA duration and corticosteroid usage and dosage were independent predictors of mortality after MI in RA. Special attention is needed for improvement of outcomes after MI in this vulnerable population.
Source: Rheumatology - March 1, 2021 Category: Rheumatology Source Type: research
Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis
Conclusion:
MTX can prevent CVEs in RA patients, but there is not sufficient evidence for using MTX to treat patients with CHD.
Source: Medicine - February 19, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort
ConclusionCIAC using HD-MTX-based protocols with OBBBD is a safe and well-tolerated procedure for the management of PCNSL. Our data suggests better PFS and survival outcomes compared to IV protocols with less hematologic toxicity and good tolerability, especially in the elderly.
Source: Frontiers in Oncology - January 20, 2021 Category: Cancer & Oncology Source Type: research
Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL
Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurologic symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The authors present a case series of 2 patients with pre-B-cell acute lymphoblastic leukemia who developed severe and ultimately ...
Source: Journal of Pediatric Hematology Oncology - October 23, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
Benefits of Methotrexate Use on Cardiovascular Disease Risk among Rheumatoid Arthritis Patients Initiating Biologic Disease-Modifying Antirheumatic Drugs.
CONCLUSION: Among RA patients receiving biologics, concomitant methotrexate use was associated with a 24% lower risk for CVD events.
PMID: 33060309 [PubMed - as supplied by publisher]
Source: J Rheumatol - October 15, 2020 Category: Rheumatology Authors: Xie F, Chen L, Yun H, Levitan EB, Curtis JR Tags: J Rheumatol Source Type: research
Targeting Inflammation to Reduce Residual Cardiovascular Risk
AbstractPurpose of ReviewPatients with established cardiovascular disease are at high risk for recurrent myocardial infarction, stroke, and cardiovascular death. The termresidual risk refers to this risk that persists, even after optimal treatment. Considerable progress has been made to understand the biological basis of residual risk and to devise therapies that can safely and effectively reduce risk. The presence of ongoing subclinical vascular inflammation is known to be a marker of elevated residual risk, and reductions in measures of vascular inflammation predict improved outcome in these patients.Recent FindingsRecen...
Source: Current Atherosclerosis Reports - September 2, 2020 Category: Cardiology Source Type: research
Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients.
In conclusion, leukoencephalopathy is well-documented for ALL patients (with a focus on methotrexate), but there is a lack of knowledge for other intravenous chemotherapeutics, other oncological populations, wider age ranges and possible risk factors (e.g. history of CNS event). Furthermore, the long-term neuropsychological impact and potential risk for neurodegenerative processes due to leukoencephalopathy remains inconclusive. Hence, large international databanks, epidemiological and prospective case-control studies are necessary to stratify risk groups for CNS-related side effects.
PMID: 32799637 [PubMed - as supplied by publisher]
Source: Journal of Chemotherapy - August 19, 2020 Category: Cancer & Oncology Tags: J Chemother Source Type: research
The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA.
PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research
